A severe case of bevacizumab-induced thrombotic microangiopathy.

Clicks: 305
ID: 51736
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #4 of 8 articles by views in Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Bevacizumab is a human monoclonal antibody against VEGF. Many adverse reactions about bevacizumab are identified including venous and arterial thromboembolism, nausea, fatigue, alopecia, proteinuria, gastrointestinal system (GIS) perforation, exfoliative dermatitis, and peripheral edema and thrombocytopenia. In this paper, we report a case of bevacizumab-induced dose-dependent, toxicity-mediated drug-induced thrombotic microangiopathy.
Reference Key
bektas2019ajournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bektas, Mert;Samancı, Nilay S;Cokgezer, Simay;Keskin, Dilek;Demirelli, Fuat H;
Journal Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Year 2019
DOI
10.1177/1078155218800371
URL
Keywords
thrombocytopenia bevacizumab dose-dependent toxicity-mediated drug-induced thrombotic microangiopathy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.